Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Mylan | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Mylan

$465 million DoJ settlement hits earnings

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Mylan

3Q Revenues: $3.1 billion (+13%)

3Q Loss: $119.8 million (earnings were $428.6 million 3Q15)

YTD Revenues: $7.8 billion (+13%)

YTD Earnings: $62.5 million (earnings were $653.1 million YTD15)

Comments: Generics segment third party sales in the quarter were $2.6 billion, up 17%. Specialty segment sales were $418.7 million, down 4%. Loss in the quarter was primarily a result of the company’s $465 million settlement with the U.S. Department of Justice and other government agencies related to the classification of the EpiPen for purposes of the Medicaid Drug Rebate Program.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters